Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
Luis (Giovanni) Giovanni Sosa
Counsel Corporate & Finance
Languages
English, Spanish
Throughout his career, he has successfully represented clients in proceedings and lawsuits related to audits, inspections, sanctions, tax assessments, and fines imposed by various authorities. He also has extensive experience in constitutional litigation challenging legal reforms that affect the interests of his clients. Giovanni has led high-impact strategic litigation in areas such as tax, environmental, energy, financial, and health law before the Supreme Court of Justice of the Nation, as well as before federal and state courts. His track record and experience in disputes with government authorities have been recognized by Chambers & Partners and The Legal 500.
Represented clients in a broad range of federal and state tax audits.
Represented multiple clients in Conclusive Agreement proceedings before PRODECON, securing significant reductions in tax contingencies.
Advised and represented companies in public procurement procedures conducted by federal and state authorities.
Represented companies in bid protest and related litigation arising from public procurement procedures.
Represented a pharmaceutical industry participant in challenges to general regulatory provisions governing the issuance of marketing authorizations.
Represented an international shipping company in constitutional proceedings before the Supreme Court of Justice of Mexico concerning the interpretation of generally applicable legislation.
Represented audit firms in litigation challenging sanctions imposed by the CNBV.
Represented food industry companies in litigation challenging enforcement actions and sanctions imposed by PROFECO.
Represented multiple clients in constitutional challenges before the Supreme Court of Justice of Mexico against green taxes enacted in 2022 by several Mexican states.
Represented a consumer products and distribution company in a constitutional challenge to state legislative reforms restricting mobility.
Represented pharmaceutical industry participants in matters involving regulatory silence and administrative inaction by the relevant health authority.